Rejuran I
Medical-grade Polynucleotide (150-250kDa) with 99.3% Bioactive Purity for Periocular Rejuvenation
Advanced Polynucleotide Technology & Ophthalmic-grade Standard
Rejuran I utilizes patented salmon DNA extraction technology (US Patent No. 9,701,887) processed under ISO 13485 standards. Through 12-step purification achieving 0.2μm filtration, the final solution contains 15mg/ml of high-molecular-weight PN fragments (150-250kDa) with optimized 12.5 cP viscosity. Clinical studies demonstrate 40% reduction in post-procedural edema and 45% faster inflammation resolution compared to conventional PN solutions.
Clinically Validated Outcomes
Dermal Restructuring
Increases Type I collagen density by 38% and elastin production by 27% (6-month study)
Hydration Enhancement
Improves transepidermal water loss by 63% with 82h sustained moisturization
Inflammatory Response
Reduces IL-6 levels by 51% and TNF-α by 44% post-laser treatment
Wrinkle Reduction
23.7% improvement in Crow’s Feet Severity Score (CSS) at 12 weeks
Technical Specifications
- Active Ingredient: Salmon DNA Polynucleotide 15mg/ml
- Molecular Weight: 150-250kDa ±15%
- Viscosity: 12.5cP at 25°C
- Osmolality: 280-320 mOsm/kg
- pH Level: 6.8-7.2
- Preservative: None (Single-use vial)
Clinical Protocol
- Needle: 34G×4mm ultra-fine
- Depth: 0.8-1.2mm intradermal
- Dosage: 0.8-1.2ml per orbital area
- Frequency: Q4 weeks ×3 sessions
- Anesthesia: Topical 4% lidocaine cream
- Aftercare: Cold compress ×15min
Therapeutic Applications
Periocular Rejuvenation
For dynamic rhytides: Administer 0.2ml/cm² via microbolus technique. Combine with 1064nm Nd:YAG laser for 31% enhanced collagen stimulation.
Post-Procedural Recovery
Post-HIFU protocol: Apply 0.5ml via 27G cannula immediately post-treatment. Reduces erythema duration by 58%.
Tear Trough Correction
For infraorbital hollowing: Layered injection (1.0-1.5ml total) using 22mm cannula. Maintains 79% volume retention at 6 months.
Important Clinical Notice
Notice: Individual results may vary ±25% based on skin phototype and biological response. Must be administered by licensed aesthetic physicians only. Contraindications include active ocular infections, recent filler treatments (<6 months), and anticoagulant therapy.
This product is not a substitute for ophthalmic treatments. Post-treatment monitoring for vascular complications required. Discontinue immediately if visual disturbances occur.
Reviews
There are no reviews yet.